Obstructive Sleep Apnea

Across the globe, health care professionals are celebrating World Sleep Day, an event created by the World Sleep Society, on March 14.

Among patients with moderate to severe obstructive sleep apnea and uncontrolled hypertension, some measures of blood pressure fell significantly with 6-month CPAP use, according to data published in Annals of the American Thoracic Society.

A 58-year-old man who lives out of state had a history of waking up with irritation in his right eye 2 weeks after sleeping in his contact lenses.

Pediatric patients with severe obstructive sleep apnea and a vitamin D deficiency faced more severe sleep apnea vs. those without this deficiency, according to results published in JAMA Otolaryngology–Head & Neck Surgery.

Moderate to severe obstructive sleep apnea was associated with significantly higher odds of having neovascular age-related macular degeneration, according to a study published in Clinical & Experimental Ophthalmology.

Individuals with a moderate to high risk for obstructive sleep apnea, as measured via the STOP-Bang questionnaire, were more likely to experience suicidal ideations, plans and attempts, according to research conducted in South Korea.

Among patients with obstructive sleep apnea, those treated with sleep surgery vs. CPAP had decreased odds for motor vehicle accident incidence, according to results published in Otolaryngology-Head and Neck Surgery.

Entering 2025, adults with moderate to severe obstructive sleep apnea and obesity have a new FDA-approved treatment option that takes the form of a GIP/GLP-1 dual agonist, according to a press release from Eli Lilly and Company.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.